Trial Profile
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Amgen
- 27 Dec 2017 New trial record
- 12 Dec 2017 Pooled safety results of NCT00095264 and NCT01362140 (n=352) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology